SEC Form 4 · accession 0000899243-18-007628
Inhibitor Therapeutics, Inc. · INTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
E. Brendan Magrab
Officer — Chairman of the Board · Director
Period of report
Mar 13, 2018
Accepted (ET)
Mar 15, 2018 · 6:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042418
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock OptionsF1 | $0.2722 | Mar 13, 2018 | A | 345,000 | A | Mar 13, 2019 | Mar 13, 2028 | Common Stock | 345,000 | 345,000 | D |
Explanation of responses
- F1These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled.